

Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

Listing of Claims:

1. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredients, (a) an opioid analgesic and (b) (+)-(B)-trans-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidiny]-N-(2,6-dimethylphenyl)-1-piperazine acetamide, a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or an N—oxide form thereof; wherein the (+)-(B)-trans-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidiny]-N-(2,6-dimethylphenyl)-1-piperazine acetamide, pharmaceutically acceptable acid or base addition salt thereof, stereochemically isomeric form thereof or N—oxide form thereof is present in an amount effective to reduce the respiratory depression caused by the administration of ~~an~~ the opioid analgesic; ~~and pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N—oxide form thereof.~~
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)

8. (Canceled)
9. (Withdrawn) A pharmaceutical composition according to claim 1 wherein, the pharmaceutical composition comprises a compound selected from the group consisting of :
 - 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-piperazine acetamide;
 - 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(1-phenylcyclohexyl)-1-piperazine acetamide;
 - 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-[-(1-pyrrolidinylcarbonyl)benzyl]-1-piperazinyl]piperidine;
 - 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-[1-[(2-methyl-5-oxazolyl)methyl]-1H-benzimidazol-2-yl]-1-piperazinyl]-2-(phenylmethyl)piperidine;
 - 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-trifluoromethylphenyl)methyl]-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-piperazine acetamide; and
 - 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-piperazine acetamide.
10. (Previously presented) A pharmaceutical composition according to claim 1 wherein, the pharmaceutical composition comprises (+)-(B)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-piperazine acetamide (L)-malic acid (1:1).
11. (Previously Presented) A pharmaceutical composition according to claim 1 wherein, the pharmaceutical composition is formulated for simultaneous, separate or sequential use.
12. (Currently amended) A pharmaceutical composition according to claim 1 wherein, the opioid analgesic is one or more compounds selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanyl, codeine, diacetylmorphine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, lofentanyl, meperidine, methadone, morphine, nalbuphine,

oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanyl, and sufentanil, ~~and derivatives~~ and pharmaceutical acceptable salts thereof.

13. (Currently amended) A pharmaceutical composition according to claim 12 wherein the opioid analgesic is one or more compounds selected from the group consisting of oxycodone, codeine, morphine, fentanyl, buprenorphine, hydrocodone, hydromorphone and pharmaceutical acceptable salts and ~~derivatives thereof~~.
14. (Previously Presented) A pharmaceutical composition according to claim 1 where, the pharmaceutical composition is in a form suitable to be orally administered.
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Withdrawn) A method for treating pain and/or nociception comprising administering to a person in need thereof an effective amount of a pharmaceutical composition according to claim 1.
22. (Withdrawn) A method for treating acute and chronic pain selected from the group consisting of inflammatory, post-operative, emergency room (ER), breakthrough, neuropathic and cancer pain comprising administering to one in

need thereof an effective amount of a pharmaceutical composition according to claim 1.

23. (Withdrawn) A method for treating emesis in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of a pharmaceutical composition according to claim 1.
24. (Withdrawn) A method for treating nausea and vomiting in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of a pharmaceutical composition according to claim 23.
25. (Withdrawn) A method for treating respiratory depression in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of an NK₁-receptor antagonist selected from an NK₁-receptor antagonist according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof.
26. (Withdrawn) A method for reducing and/or overcoming the tolerance observed with opioids in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of an NK₁-receptor antagonist selected from the group consisting of an NK₁-receptor antagonist according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof.